Compare SHBI & FTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SHBI | FTH |
|---|---|---|
| Founded | 1876 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 757.4M | 835.7M |
| IPO Year | 1997 | 2021 |
| Metric | SHBI | FTH |
|---|---|---|
| Price | $23.45 | $35.75 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $19.17 | N/A |
| AVG Volume (30 Days) | 131.0K | ★ 291.5K |
| Earning Date | 04-23-2026 | N/A |
| Dividend Yield | ★ 2.51% | N/A |
| EPS Growth | ★ 34.85 | N/A |
| EPS | ★ 1.07 | N/A |
| Revenue | ★ $20,853,000.00 | N/A |
| Revenue This Year | $8.97 | N/A |
| Revenue Next Year | $6.26 | N/A |
| P/E Ratio | $21.91 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $14.93 | $17.50 |
| 52 Week High | $24.89 | $42.14 |
| Indicator | SHBI | FTH |
|---|---|---|
| Relative Strength Index (RSI) | 53.54 | 61.99 |
| Support Level | $23.43 | $31.03 |
| Resistance Level | $23.68 | $42.14 |
| Average True Range (ATR) | 0.41 | 3.31 |
| MACD | 0.03 | 0.14 |
| Stochastic Oscillator | 84.96 | 70.62 |
Shore Bancshares Inc is a financial holding company based in the United States. Through its subsidiaries, it provides consumer and commercial banking products and services, as well as secondary mortgage lending, trust, wealth management, and financial planning services. The group caters to both business and individual clients, offering checking, savings, certificates of deposit, and overnight investment sweep accounts; commercial lending services, including secured and unsecured loans, working capital loans, lines of credit, etc; and safe deposit boxes, debit cards, telephone banking, and other financial products and services.
Faeth Therapeutics Inc is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The company's principal program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer.